Compare PSN & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSN | CYTK |
|---|---|---|
| Founded | 1944 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.3B |
| IPO Year | 2019 | 2004 |
| Metric | PSN | CYTK |
|---|---|---|
| Price | $64.69 | $70.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 17 |
| Target Price | $84.00 | ★ $85.59 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.77 | 3.49 |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $6,364,245,000.00 | $13,368,000.00 |
| Revenue This Year | $6.45 | $341.94 |
| Revenue Next Year | $7.69 | $48.30 |
| P/E Ratio | $29.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.56 | $29.31 |
| 52 Week High | $89.50 | $70.98 |
| Indicator | PSN | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 56.80 |
| Support Level | $60.45 | $59.23 |
| Resistance Level | $70.39 | $67.75 |
| Average True Range (ATR) | 2.27 | 2.38 |
| MACD | -0.15 | 0.33 |
| Stochastic Oscillator | 51.76 | 79.93 |
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.